The-Verdict-Is-In_InsightRx_Header
March 20, 2020

The Verdict is in: Why pharmacies should rapidly adopt new vancomycin dosing guidelines

Prescribed to millions of U.S. patients each year, vancomycin is considered the treatment of choice for serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and is prescribed for other susceptible Gram-positive organisms. While effective, it can cause nephrotoxicity, which can result in longer lengths of stay, higher costs, and higher mortality rates.

Since dosing guidelines were last issued in 2009, multiple studies have demonstrated that replacing traditional dosing strategies based on vancomycin trough levels with newer area-under- the-curve (AUC) approaches can reduce nephrotoxicity while maintaining or enhancing clinical efficacy.

As a result, new 2020 consensus clinical guidelines call for hospitals to use AUC-based dosing strategies to enhance patient safety. Currently, however, awareness of these guidelines and preparedness to implement them appears to be low.

Read more in the white paper below.

The-Verdict-is-In-InsightRX-Vancomycin-White-PaperDownload